AbbVie cites growth of immunology business in the second quarter

2 months ago 20
PR Distribution

An earlier mentation of this study incorrectly cited AbbVie's updated EPS guidance for 2021. It has been corrected.

AbbVie Inc. ABBV, +0.27% bushed expectations for the 2nd 4th of 2021, driven mostly by gains successful its immunology business. The cause shaper had net of $766 million, oregon 42 cents per share, successful the 2nd 4th of 2021. It had a nonaccomplishment of $738 million, oregon 46 cents per share, successful the aforesaid 4th a twelvemonth ago. Adjusted net per stock were $3.11, against a FactSet statement of $3.08. AbbVie said its gross jumped to $13.9 cardinal for the quarter, up from $10.4 cardinal successful the aforesaid play a twelvemonth ago. The FactSet statement was $13.6 billion. The institution said income of respective marquee drugs accrued successful the 2nd quarter, including arthritis therapy Humira to $5.0 cardinal and Botox Cosmetic, which the cause shaper gained arsenic portion of its acquisition of Allergan, to $584 million. The institution updated its guidance for the year, saying it present expects EPS of $6.04 to $6.14, compared with past guidance of $7.27 to $7.47. It besides updated guidance for adjusted EPS and present expects a scope of $12.52 to $12.62, compared with erstwhile guidance of $12.37 to $12.57. AbbVie's banal is up 10.4% truthful acold this year, portion the broader S&P 500 SPX, +0.42% is up 17.6%.

Read Entire Article